May 15, 2012 Eliminating Tuberculosis and Tuberculosis-HIV Co-Disease in the 21st Century: Key Perspectives, Controversies, Unresolved Issues, and Needs
May 15, 2012 Drug-Resistant Tuberculosis–Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs
May 2, 2012 Renewed Focus on Tuberculosis Holds Promise for New Treatments FDA approved rifampin for the treatment of tuberculosis (TB) in 1971, the same year Intel Corporation invented the first microproc
April 25, 2012 Tucson institute plays critical cancer role Re: the April 19 article “Vast study advances breast cancer fight.”
April 24, 2012 ACRO Testifies Before FDA on Clinical Trial Modernization WASHINGTON–(BUSINESS WIRE)– The Association of Clinical Research Organizations (ACRO) today provided the FDA with a nu
April 21, 2012 C-Path Initiative’s Work on Personalized Medicine Starts to Get Results The Critical path Institute (C-Path), the US Food and Drug Administration (FDA)-supported public-private initiative working to adv
April 18, 2012 C-Path Looks to Speed Gene Based Therapies Your doctor may soon – perhaps in a year – be able to order up a test to map out your entire genome, or genetic bluepr
April 15, 2012 Future of medicine – the critical path forward I saw a presentation yesterday by Carolyn Compton, the new head of C-PATH, the critical path institute located in Tucson, AZ. This
April 14, 2012 Critical Path Institute Announces New Head of Operations Critical Path Institute (C-Path) has announced that Steven T. Broadbent has been chosen as the next chief operating officer of C-P
